Clinical Trial Update: Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating Ublituximab (Briumvi) for early forms of relapsing multiple sclerosis is currently recruiting. Sponsored by Northwestern Uni…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• BRIUMVI (ublituximab)

Snippet

Sponsor: Northwestern University | Conditions: Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting | Phase 4 | Status: RECRUITING